These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 825592)

  • 1. Use of Amikacin in a hospital for children: microbiological and clinical studies.
    Marget W; Reindke B; Versmold H
    J Infect Dis; 1976 Nov; 134 SUPPL():S412-9. PubMed ID: 825592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amikacin in obstetric, gynecologic, and neonatal infections: laboratory and clinical studies.
    Mazzei T; Paradiso M; Nicoletti I; Periti P
    J Infect Dis; 1976 Nov; 134 SUPPL():S374-9. PubMed ID: 993629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gentamicin-resistant bacillary infection. Clinical features and amikacin therapy.
    Leonard JM; McGee ZA; Alford RH
    Arch Intern Med; 1978 Feb; 138(2):201-5. PubMed ID: 415674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of current clinical isolates of Pseudomonas aeruginosa and enteric gram-negative bacilli to amikacin and other aminoglycoside antibiotics.
    Dámaso D; Moreno-López M; Martínez-Beltrán J; García-Iglesias MC
    J Infect Dis; 1976 Nov; 134 SUPPL():S394-90. PubMed ID: 825591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Amikacin resistance of clinical strains of Enterobacteriaceae and Pseudomonas].
    Moreva TV; Anisimova LA; Erova TE; Boronin AM
    Antibiot Khimioter; 1992 Apr; 37(4):25-8. PubMed ID: 1417311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility of recently isolated gram-negative bacteria to gentamicin, sisomicin, tobramycin, and amikacin.
    Knothe H
    J Infect Dis; 1976 Nov; 134 SUPPL():S271-4. PubMed ID: 825585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and laboratory studies with amikacin in newborns, infants, and children.
    Trujillo H; Manotas R; Londono R; Ramirez JI; Uribe A; De Vidal EL; Agudelo N
    J Infect Dis; 1976 Nov; 134 SUPPL():S406-11. PubMed ID: 993632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of a synergistic combination of cefotaxime and amikacin against multiresistant Pseudomonas and Serratia infections.
    Maslow MJ; Simberkoff MS; Rahal JJ
    J Antimicrob Chemother; 1985 Aug; 16(2):227-34. PubMed ID: 3934125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of amikacin in treatment of infections due to gram-negative aerobic bacilli.
    Mathias RG; Ronald AR; Gurwith MJ; McCullough DW; Stiver HG; Berger J; Cates CY; Fox LM; Lank BA
    J Infect Dis; 1976 Nov; 134 SUPPL():S394-401. PubMed ID: 825590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amikacin therapy for severe gram-negative sepsis: efficacy in infections involving gentamicin-resistant organisms.
    Tally FP; Louie TJ; O'Keefe P; Gorbach SL; Bartlett JG
    J Infect Dis; 1976 Nov; 134 SUPPL():S428-32. PubMed ID: 993634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of pediatric infections with amikacin as first-line aminoglycoside.
    Shulman ST; Yogev R
    Am J Med; 1985 Jul; 79(1A):43-50. PubMed ID: 4025367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin.
    Ruiz-Palacios GM; Ponce de Leon S; Sifuentes J; Ponce de Leon S; Calva JJ; Huazano F; Ontiveros C; Ojeda F; Bobadilla M
    Am J Med; 1986 Jun; 80(6B):71-5. PubMed ID: 3089006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative evaluation of five aminoglycosides for treatment.
    Rosin H; Naumann P; Reintjens E; Köhler M
    Int J Clin Pharmacol Biopharm; 1976 Apr; 13(3):157-67. PubMed ID: 820656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the in vitro activities of BB-K8 and three other aminoglycosides against 215 strains of Pseudomonas and Enterobacteriaceae with variable sensitivity to kanamycin and gentamicin.
    Yourassowsky E; Schoutens E; Vanderlinden MP
    Chemotherapy; 1975; 21(1):45-51. PubMed ID: 807457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of results of clinical trials with amikacin.
    Gooding PG; Berman E; Lane AZ; Agre K
    J Infect Dis; 1976 Nov; 134 SUPPL():S441-5. PubMed ID: 792360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The antimicrobial activity of amikacin in comparison with three other aminoglycoside-antibiotics (author's transl)].
    Jotzoff M
    Med Klin; 1978 Jun; 73(24):914-7. PubMed ID: 661734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outbreak of amikacin-resistant Enterobacteriaceae in an intensive care nursery.
    Cook LN; Davis RS; Stover BH
    Pediatrics; 1980 Feb; 65(2):264-8. PubMed ID: 6986597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of chronologic age on the serum concentrations of amikacin in sick term and premature infants.
    Prober CG; Yeager AS; Arvin AM
    J Pediatr; 1981 Apr; 98(4):636-40. PubMed ID: 7205495
    [No Abstract]   [Full Text] [Related]  

  • 19. Suceptibility of aminoglycoside-resistant gram-negative bacilli to amikacin: delineation of individual resistance patterns.
    Acar JF; Witchitz JL; Goldstein F; Talbot JN; Le Goffic F
    J Infect Dis; 1976 Nov; 134 SUPPL():S280-5. PubMed ID: 825587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amikacin therapy for serious gram-negative infection.
    Pollock AA; Berger SA; Richmond AS; Simberkoff MS; Rahal JJ
    JAMA; 1977 Feb; 237(6):562-4. PubMed ID: 576282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.